Publisher: Adis International
ISSN: 1174-5886
Source: Drugs in R&D, Vol.3, Iss.2, 2002-02, pp. : 141-142
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Adis CommentsAzmacort HFA [RG 5016] is a non-chlorofluorocarbon (CFC) inhalation formulation of the off-patent corticosteroid, triamcinolone acetonide, developed by Aventis Pharma using hydrofluoroalkane (HFA-134a) propellant. It is indicated for the preventative management of asthma. The 75g formulation and the high-potency 225g formulation were deemed approvable by the US FDA in March 1998 and April 1999, respectively. Both formulations are in phase III clinical trials in Europe. In December 2001, Aventis formed an agreement with ViroPharma regarding the co-promotion of triamcinolone acetonide in the USA.